PMID- 31954081
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 92
IP  - 4
DP  - 2020 Apr
TI  - Correlation between glucose metabolism and serum steroid hormones in patients 
      with polycystic ovary syndrome.
PG  - 350-357
LID - 10.1111/cen.14154 [doi]
AB  - OBJECTIVE: Polycystic ovary syndrome (PCOS) is associated with an increased 
      prevalence of dysglycaemia, which includes impaired glucose tolerance and type 2 
      diabetes mellitus (T2DM). Patients with PCOS demonstrate abnormal patterns of 
      steroid hormones. Here, we analyse the correlation between glucose metabolism and 
      serum steroid hormones in PCOS. DESIGN: Observational double-centre study. 
      PATIENTS: 914 patients with PCOS. MEASUREMENTS: We assessed the glucose 
      metabolism status of all patients according to the 1999 WHO criteria. Serum 
      steroid hormones were measured by liquid chromatography-tandem mass spectrometry. 
      RESULTS: The median age of the patients was 26 years (interquartile range: 
      21-30), and 40.6% (371/914) had abnormal glucose metabolism: 29.3% (268/914) had 
      prediabetes, and 11.3% (103/914) had T2DM. Correlation analysis not adjusting for 
      confounding factors revealed that serum aldosterone, androstenedione, oestrone, 
      pregnenolone and the free androgen index were positively correlated, while 
      progesterone was negatively correlated with the risk of abnormal glucose 
      metabolism. After adjusting for age, body mass index and fasting insulin levels 
      in the logistic regression model, only aldosterone (P = .013), androstenedione 
      (P = .046) and oestrone (P = .014; in quartiles) were correlated with the risk of 
      abnormal glucose metabolism. CONCLUSIONS: This study indicates a high prevalence 
      of prediabetes and T2DM in patients with PCOS. Furthermore, there were positive 
      correlations of serum aldosterone, androstenedione and oestrone with the risk of 
      abnormal glucose metabolism after adjusting for confounding factors.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Li, Xuelin
AU  - Li X
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Zhang, Tianyue
AU  - Zhang T
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Li, Shengxian
AU  - Li S
AD  - Department of Endocrinology, Renji Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai, China.
FAU - Deng, Yuying
AU  - Deng Y
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Wang, Lihua
AU  - Wang L
AD  - Department of Endocrinology, Renji Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai, China.
FAU - Tao, Tao
AU  - Tao T
AUID- ORCID: 0000-0003-4228-8252
AD  - Department of Endocrinology, Renji Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai, China.
FAU - Wang, Shujie
AU  - Wang S
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Gu, Yanyun
AU  - Gu Y
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Gu, Weiqiong
AU  - Gu W
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Hong, Jie
AU  - Hong J
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Endocrinology, Renji Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai, China.
FAU - Wang, Weiqing
AU  - Wang W
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Zhang, Yifei
AU  - Zhang Y
AUID- ORCID: 0000-0003-0272-0602
AD  - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, 
      State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200129
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Androgens)
RN  - 0 (Steroids)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
CIN - Clin Endocrinol (Oxf). 2020 Sep;93(3):355. PMID: 32026483
MH  - Androgens
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Glucose
MH  - Humans
MH  - Infant, Newborn
MH  - *Polycystic Ovary Syndrome
MH  - Steroids
OTO - NOTNLM
OT  - aldosterone
OT  - androstenedione
OT  - liquid chromatography-tandem mass spectrometry
OT  - oestrone
OT  - polycystic ovary syndrome
OT  - steroid hormones
OT  - type 2 diabetes mellitus
EDAT- 2020/01/19 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/01/19 06:00
PHST- 2019/05/30 00:00 [received]
PHST- 2020/01/05 00:00 [revised]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/01/19 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/01/19 06:00 [entrez]
AID - 10.1111/cen.14154 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2020 Apr;92(4):350-357. doi: 10.1111/cen.14154. Epub 2020 
      Jan 29.